The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Myeloid Leukemia (CML) Treatment Market Research Report 2025
Synopsis
Chronic myeloid leukaemia (CML) is a type cancer that affects the blood and bone marrow.
The global Chronic Myeloid Leukemia (CML) Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Myeloid Leukemia (CML) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Myeloid Leukemia (CML) Treatment.
Report Scope
The Chronic Myeloid Leukemia (CML) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Myeloid Leukemia (CML) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Myeloid Leukemia (CML) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis AG
Bristol-Myers Squibb
Teva Pharmaceuticals Industries Ltd.
ARIAD Pharmaceuticals, Inc.
Pfizer, Inc.
Hospira, Inc.
Prism Pharmaceuticals
Incyte Corporation
Bio-Path Holdings
Stragen Pharma SA
Otsuka Pharmaceutical Co., Ltd.
Segment by Type
Targeted Therapy
Chemotherapy
Radiation Therapy
Splenectomy
Stem Cell Transplant
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Myeloid Leukemia (CML) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Chronic myeloid leukaemia (CML) is a type cancer that affects the blood and bone marrow.
The global Chronic Myeloid Leukemia (CML) Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Myeloid Leukemia (CML) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Myeloid Leukemia (CML) Treatment.
Report Scope
The Chronic Myeloid Leukemia (CML) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Myeloid Leukemia (CML) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Myeloid Leukemia (CML) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis AG
Bristol-Myers Squibb
Teva Pharmaceuticals Industries Ltd.
ARIAD Pharmaceuticals, Inc.
Pfizer, Inc.
Hospira, Inc.
Prism Pharmaceuticals
Incyte Corporation
Bio-Path Holdings
Stragen Pharma SA
Otsuka Pharmaceutical Co., Ltd.
Segment by Type
Targeted Therapy
Chemotherapy
Radiation Therapy
Splenectomy
Stem Cell Transplant
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chronic Myeloid Leukemia (CML) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Myeloid Leukemia (CML) Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Targeted Therapy
1.2.3 Chemotherapy
1.2.4 Radiation Therapy
1.2.5 Splenectomy
1.2.6 Stem Cell Transplant
1.3 Market by Application
1.3.1 Global Chronic Myeloid Leukemia (CML) Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Myeloid Leukemia (CML) Treatment Market Perspective (2019-2030)
2.2 Chronic Myeloid Leukemia (CML) Treatment Growth Trends by Region
2.2.1 Global Chronic Myeloid Leukemia (CML) Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Chronic Myeloid Leukemia (CML) Treatment Historic Market Size by Region (2019-2024)
2.2.3 Chronic Myeloid Leukemia (CML) Treatment Forecasted Market Size by Region (2025-2030)
2.3 Chronic Myeloid Leukemia (CML) Treatment Market Dynamics
2.3.1 Chronic Myeloid Leukemia (CML) Treatment Industry Trends
2.3.2 Chronic Myeloid Leukemia (CML) Treatment Market Drivers
2.3.3 Chronic Myeloid Leukemia (CML) Treatment Market Challenges
2.3.4 Chronic Myeloid Leukemia (CML) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Myeloid Leukemia (CML) Treatment Players by Revenue
3.1.1 Global Top Chronic Myeloid Leukemia (CML) Treatment Players by Revenue (2019-2024)
3.1.2 Global Chronic Myeloid Leukemia (CML) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Chronic Myeloid Leukemia (CML) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Chronic Myeloid Leukemia (CML) Treatment Revenue
3.4 Global Chronic Myeloid Leukemia (CML) Treatment Market Concentration Ratio
3.4.1 Global Chronic Myeloid Leukemia (CML) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Myeloid Leukemia (CML) Treatment Revenue in 2023
3.5 Chronic Myeloid Leukemia (CML) Treatment Key Players Head office and Area Served
3.6 Key Players Chronic Myeloid Leukemia (CML) Treatment Product Solution and Service
3.7 Date of Enter into Chronic Myeloid Leukemia (CML) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Myeloid Leukemia (CML) Treatment Breakdown Data by Type
4.1 Global Chronic Myeloid Leukemia (CML) Treatment Historic Market Size by Type (2019-2024)
4.2 Global Chronic Myeloid Leukemia (CML) Treatment Forecasted Market Size by Type (2025-2030)
5 Chronic Myeloid Leukemia (CML) Treatment Breakdown Data by Application
5.1 Global Chronic Myeloid Leukemia (CML) Treatment Historic Market Size by Application (2019-2024)
5.2 Global Chronic Myeloid Leukemia (CML) Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Chronic Myeloid Leukemia (CML) Treatment Market Size (2019-2030)
6.2 North America Chronic Myeloid Leukemia (CML) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Chronic Myeloid Leukemia (CML) Treatment Market Size by Country (2019-2024)
6.4 North America Chronic Myeloid Leukemia (CML) Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Myeloid Leukemia (CML) Treatment Market Size (2019-2030)
7.2 Europe Chronic Myeloid Leukemia (CML) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Chronic Myeloid Leukemia (CML) Treatment Market Size by Country (2019-2024)
7.4 Europe Chronic Myeloid Leukemia (CML) Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market Size (2019-2030)
8.2 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Chronic Myeloid Leukemia (CML) Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Myeloid Leukemia (CML) Treatment Market Size (2019-2030)
9.2 Latin America Chronic Myeloid Leukemia (CML) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Chronic Myeloid Leukemia (CML) Treatment Market Size by Country (2019-2024)
9.4 Latin America Chronic Myeloid Leukemia (CML) Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Market Size (2019-2030)
10.2 Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Chronic Myeloid Leukemia (CML) Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Detail
11.1.2 Novartis AG Business Overview
11.1.3 Novartis AG Chronic Myeloid Leukemia (CML) Treatment Introduction
11.1.4 Novartis AG Revenue in Chronic Myeloid Leukemia (CML) Treatment Business (2019-2024)
11.1.5 Novartis AG Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Detail
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Chronic Myeloid Leukemia (CML) Treatment Introduction
11.2.4 Bristol-Myers Squibb Revenue in Chronic Myeloid Leukemia (CML) Treatment Business (2019-2024)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Teva Pharmaceuticals Industries Ltd.
11.3.1 Teva Pharmaceuticals Industries Ltd. Company Detail
11.3.2 Teva Pharmaceuticals Industries Ltd. Business Overview
11.3.3 Teva Pharmaceuticals Industries Ltd. Chronic Myeloid Leukemia (CML) Treatment Introduction
11.3.4 Teva Pharmaceuticals Industries Ltd. Revenue in Chronic Myeloid Leukemia (CML) Treatment Business (2019-2024)
11.3.5 Teva Pharmaceuticals Industries Ltd. Recent Development
11.4 ARIAD Pharmaceuticals, Inc.
11.4.1 ARIAD Pharmaceuticals, Inc. Company Detail
11.4.2 ARIAD Pharmaceuticals, Inc. Business Overview
11.4.3 ARIAD Pharmaceuticals, Inc. Chronic Myeloid Leukemia (CML) Treatment Introduction
11.4.4 ARIAD Pharmaceuticals, Inc. Revenue in Chronic Myeloid Leukemia (CML) Treatment Business (2019-2024)
11.4.5 ARIAD Pharmaceuticals, Inc. Recent Development
11.5 Pfizer, Inc.
11.5.1 Pfizer, Inc. Company Detail
11.5.2 Pfizer, Inc. Business Overview
11.5.3 Pfizer, Inc. Chronic Myeloid Leukemia (CML) Treatment Introduction
11.5.4 Pfizer, Inc. Revenue in Chronic Myeloid Leukemia (CML) Treatment Business (2019-2024)
11.5.5 Pfizer, Inc. Recent Development
11.6 Hospira, Inc.
11.6.1 Hospira, Inc. Company Detail
11.6.2 Hospira, Inc. Business Overview
11.6.3 Hospira, Inc. Chronic Myeloid Leukemia (CML) Treatment Introduction
11.6.4 Hospira, Inc. Revenue in Chronic Myeloid Leukemia (CML) Treatment Business (2019-2024)
11.6.5 Hospira, Inc. Recent Development
11.7 Prism Pharmaceuticals
11.7.1 Prism Pharmaceuticals Company Detail
11.7.2 Prism Pharmaceuticals Business Overview
11.7.3 Prism Pharmaceuticals Chronic Myeloid Leukemia (CML) Treatment Introduction
11.7.4 Prism Pharmaceuticals Revenue in Chronic Myeloid Leukemia (CML) Treatment Business (2019-2024)
11.7.5 Prism Pharmaceuticals Recent Development
11.8 Incyte Corporation
11.8.1 Incyte Corporation Company Detail
11.8.2 Incyte Corporation Business Overview
11.8.3 Incyte Corporation Chronic Myeloid Leukemia (CML) Treatment Introduction
11.8.4 Incyte Corporation Revenue in Chronic Myeloid Leukemia (CML) Treatment Business (2019-2024)
11.8.5 Incyte Corporation Recent Development
11.9 Bio-Path Holdings
11.9.1 Bio-Path Holdings Company Detail
11.9.2 Bio-Path Holdings Business Overview
11.9.3 Bio-Path Holdings Chronic Myeloid Leukemia (CML) Treatment Introduction
11.9.4 Bio-Path Holdings Revenue in Chronic Myeloid Leukemia (CML) Treatment Business (2019-2024)
11.9.5 Bio-Path Holdings Recent Development
11.10 Stragen Pharma SA
11.10.1 Stragen Pharma SA Company Detail
11.10.2 Stragen Pharma SA Business Overview
11.10.3 Stragen Pharma SA Chronic Myeloid Leukemia (CML) Treatment Introduction
11.10.4 Stragen Pharma SA Revenue in Chronic Myeloid Leukemia (CML) Treatment Business (2019-2024)
11.10.5 Stragen Pharma SA Recent Development
11.11 Otsuka Pharmaceutical Co., Ltd.
11.11.1 Otsuka Pharmaceutical Co., Ltd. Company Detail
11.11.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
11.11.3 Otsuka Pharmaceutical Co., Ltd. Chronic Myeloid Leukemia (CML) Treatment Introduction
11.11.4 Otsuka Pharmaceutical Co., Ltd. Revenue in Chronic Myeloid Leukemia (CML) Treatment Business (2019-2024)
11.11.5 Otsuka Pharmaceutical Co., Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
